Influence of mannan and glucan on complement activation and C3 binding by Candida albicans

Infection and Immunity

Volumn 78, Issue 3, 2010, Pages 1250-1259

  Boxx, Gayle M ^a   Kozel, Thomas R ^b   Nishiya, Casey T ^a   Zhang, Mason X ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; COMPLEMENT COMPONENT C3; GLUCAN; MANNAN; PERIODATE; SODIUM BOROHYDRIDE;

ARTICLE; CANDIDA ALBICANS; CELL INTERACTION; CONTROLLED STUDY; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; YEAST CELL;

CANDIDA ALBICANS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT PATHWAY, ALTERNATIVE; GLUCANS; HUMANS; IMMUNOLOGIC FACTORS; MANNANS; NEUTROPHILS; OPSONIN PROTEINS; PHAGOCYTOSIS; PROTEIN BINDING;

EID: 77349120024     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00744-09     Document Type: Article

References (52)

1. Auger, P., C. Dumas, and J. Joly. 1979. A study of 666 strains of Candida albicans: correlation between serotype and susceptibility to 5-fluorocytosine. J. Infect. Dis. 139:590-594.
2. Bjornson, A. B., P. I. Magnafichi, R. D. Schreiber, and H. S. Bjornson. 1987. Opsonization of bacteroides by the alternative complement pathway reconstructed from isolated plasma proteins. J. Exp. Med. 165:777-798.
3. Boxx, G. M., C. T. Nishiya, T. R. Kozel, and M. X. Zhang. 2009. Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans. Mol. Immunol. 46:473-480.
4. Brandhorst, T. T., M. Wuthrich, T. Warner, and B. Klein. 1999. Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis. J. Exp. Med. 189:1207-1216.
5. Brawner, D. L., and J. E. Cutler. 1989. Oral Candida albicans isolates from nonhospitalized normal carriers, immunocompetent hospitalized patients, and immunocompromised patients with or without acquired immunodeficiency syndrome. J. Clin. Microbiol. 27:1335-1341.
6. Bromuro, C., A. Torosantucci, P. Chiani, S. Conti, L. Polonelli, and A. Cassone. 2002. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70:5462-5470.
7. Calderone, R. A., and P. C. Braun. 1991. Adherence and receptor relationships of Candida albicans. Microbiol. Rev. 55:1-20.
8. Chiani, P., C. Bromuro, A. Cassone, and A. Torosantucci. 2009. Anti-betaglucan antibodies in healthy human subjects. Vaccine 27:513-519.
9. Cutler, J. E. 2005. Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr. Mol. Med. 5:383-392.
10. Czop, J. K., and K. F. Austen. 1985. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor. J. Immunol. 135:3388-3393.
11. Fearon, D. T., and K. F. Austen. 1977. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. U. S. A. 74: 1683-1687.
12. Fine, D. P., S. R. Marney, Jr., D. G. Colley, J. S. Sergent, and R. M. Des Prez. 1972. C3 shunt activation in human serum chelated with EGTA. J. Immunol. 109:807-809.
13. Gelfand, J. A., D. L. Hurley, A. S. Fauci, and M. M. Frank. 1978. Role of complement in host defense against experimental disseminated candidiasis. J. Infect. Dis. 138:9-16.
14. Goldstein, I. J., G. W. Hay, B. A. Lewis, and F. Smith. 1965. Controlled degradation of polysaccharides by periodate oxidation, reduction, and hydrolysis, p. 361-370. In General polysaccharides, vol. V. Academic Press, Inc., New York, NY.
15. Hamuro, J., U. Hadding, and D. Bitter-Suermann. 1978. Solid phase activation of alternative pathway of complement by beta-1,3-glucans and its possible role for tumour regressing activity. Immunology 34:695-705.
16. Han, Y., T. Kanbe, R. Cherniak, and J. E. Cutler. 1997. Biochemical characterization of Candida albicans epitopes that can elicit protective and non-protective antibodies. Infect. Immun. 65:4100-4107.
17. Han, Y., T. R. Kozel, M. X. Zhang, R. S. MacGill, M. C. Carroll, and J. E. Cutler. 2001. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol. 167:1550-1557.
18. Harada, T., A. Misaki, and H. Saito. 1968. Curdlan: a bacterial gel-forming β-1,3-glucan. Arch. Biochem. Biophys. 124:292-298.
19. Hasenclever, H. F., and W. O. Mitchell. 1961. Antigenic studies of Candida. I. Observation of two antigenic groups in Candida albicans. J. Bacteriol. 82:570-573.
20. Held, K., S. Thiel, M. Loos, and F. Petry. 2008. Increased susceptibility of complement factor B/C2 double knockout mice and mannan-binding lectin knockout mice to systemic infection with Candida albicans. Mol. Immunol. 45:3934-3941.
21. Inal, S., K. Nagaki, S. Ebisu, K. Kato, and S. Kotani. 1976. Activation of the alternative complement pathway by water-insoluble glucans of streptococcus mutans: the relation between their chemical structures and activating potencies. J. Immunol. 117:1256-1260.
22. Iorio, E., A. Torosantucci, C. Bromuro, P. Chiani, A. Ferretti, M. Giannini, A. Cassone, and F. Podo. 2008. Candida albicans cell wall comprises a branched β-D-(136)-glucan with β-D-(1→33)-side chains. Carbohydr. Res. 343:1050-1061.
23. Keller, R. G., G. S. Pfrommer, and T. R. Kozel. 1994. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect. Immun. 62:215-220.
24. Klein, B. S., P. M. Sondel, and J. M. Jones. 1992. WI-1, a novel 120-kilodalton surface protein on Blastomyces dermatitidis yeast cells, is a target antigen of cell-mediated immunity in human blastomycosis. Infect. Immun. 60:4291-4300.
25. Kozel, T. R., R. R. Brown, and G. S. Pfrommer. 1987. Activation and binding of C3 by Candida albicans. Infect. Immun. 55:1890-1894.
26. Kozel, T. R., R. S. MacGill, A. Percival, and Q. Zhou. 2004. Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect. Immun. 72:209-218.
27. Kozel, T. R., and G. S. Pfrommer. 1986. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect. Immun. 52:1-5.
28. Kozel, T. R., L. C. Weinhold, and D. M. Lupan. 1996. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect. Immun. 64:3360-3368.
29. Kozel, T. R., M. A. Wilson, T. P. Farrell, and S. M. Levitz. 1989. Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae. Infect. Immun. 57:3412-3417.
30. Law, S. K., N. A. Lichtenberg, and R. P. Levine. 1979. Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J. Immunol. 123:1388-1394.
31. Lehmann, P. F., and E. Reiss. 1980. Comparison by ELISA of serum anti-Candida albicans mannan IgG levels of a normal population and in diseased patients. Mycopathologia 70:89-93.
32. Levitz, S. M., and A. Tabuni. 1991. Binding of Cryptococcus neoformans by human cultured macrophages: requirements for multiple complement receptors and actin. J. Clin. Invest. 87:528-535.
33. Matsushita, M. 1990. Curdlan, a (1-3)-β-D-glucan from Alcaligenes faecalis var. myxogenes IFO13140, activates the alternative complement pathway by heat treatment. Immunol. Lett. 26:95-97.
34. Meri, T., A. Hartmann, D. Lenk, R. Eck, R. Wurzner, J. Hellwage, S. Meri, and P. F. Zipfel. 2002. The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect. Immun. 70:5185-5192.
35. Pangburn, M. K., and H. J. Muller-Eberhard. 1984. The alternative pathway of complement. Springer Semin. Immunopathol. 7:163-192.
36. Pangburn, M. K., K. L. Pangburn, V. Koistinen, S. Meri, and A. K. Sharma. 2000. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J. Immunol. 164:4742-4751.
37. Read, S. M., G. Currie, and A. Bacic. 1996. Analysis of the structural heterogeneity of laminarin by electrospray-ionization-mass spectrometry. Carbohydr. Res. 281:187-201.
38. Schreiber, R. D., M. K. Pangburn, P. H. Lesavre, and H. J. Muller-Eberhard. 1978. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc. Natl. Acad. Sci. U. S. A. 75:3948-3952.
39. Suzuki, S. 1997. Immunochemical study on mannans of genus Candida. I. Structural Invest. of antigenic factors 1, 4, 5, 6, 8, 9, 11, 13, 13b, and 34. Curr. Top. Med. Mycol. 8:57-70.
40. Torosantucci, A., C. Bromuro, P. Chiani, F. De Bernardis, F. Berti, C. Galli, F. Norelli, C. Bellucci, L. Polonelli, P. Costantino, R. Rappuoli, and A. Cassone. 2005. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202:597-606.
41. Torosantucci, A., P. Chiani, C. Bromuro, F. De Bernardis, A. S. Palma, Y. Liu, G. Mignogna, B. Maras, M. Colone, A. Stringaro, S. Zamboni, T. Feizi, and A. Cassone. 2009. Protection by anti-beta-glucan antibodies is associated with restricted β-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS. One 4:e5392.
42. Tsoni, S. V., A. M. Kerrigan, M. J. Marakalala, N. Srinivasan, M. Duffield, P. R. Taylor, M. Botto, C. Steele, and G. D. Brown. 2009. Complement C3 plays an essential role in the control of opportunistic fungal infections. Infect. Immun. 77:3679-3685.
43. Unkeless, J. C. 1989. Function and heterogeneity of human Fc receptors for immunoglobulin G. J. Clin. Invest. 83:355-361.
44. Wheeler, R. T., and G. R. Fink. 2006. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2:e35.
45. Wheeler, R. T., D. Kombe, S. D. Agarwala, and G. R. Fink. 2008. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog. 4:e1000227.
46. Wilson, M. A., and T. R. Kozel. 1992. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 60:754-761.
47. Zhang, M. X., M. C. Bohlman, C. Itatani, D. R. Burton, P. W. Parren, S. C. St Jeor, and T. R. Kozel. 2006. Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect. Immun. 74:362-369.
48. Zhang, M. X., T. T. Brandhorst, T. R. Kozel, and B. S. Klein. 2001. Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast. Infect. Immun. 69:7559-7564.
49. Zhang, M. X., and B. Klein. 1997. Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis. Infect. Immun. 65:1849-1855.
50. Zhang, M. X., and T. R. Kozel. 1998. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect. Immun. 66:4845-4850.
51. Zhang, M. X., D. M. Lupan, and T. R. Kozel. 1997. Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect. Immun. 65:3822-3827.
52. Zipfel, P. F., R. Wurzner, and C. Skerka. 2007. Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol. Immunol. 44:3850-3857.